Nizar Souayah, MD, FAAN, FAANEM, FANA, explains why identifying the antibody subtype in MG is essential for treatment decisions. He outlines how therapies differ between acetylcholine receptor-positive disease and MuSK-positive disease.
How does understanding neuromuscular junction pathology, acetylcholine receptor versus muscle-specific kinase, inform your strategy?
Transcript
The distinction directly changes how we treat, what you expect, and which therapies that help or harm. So it is very important to distinguish the antibodies mechanism.
Acetylcholine receptor-positive disease is complement mediated, driven predominantly by immunoglobulin G1 and G3. It responds to the conventional therapy such as cholinesterase inhibitor, corticosteroids, steroid-sparing agents, and, in appropriate patients, thymectomy. Complement-directed therapy has a clear mechanism rationale in this group.
In addition, FcRn inhibitors and IVIG can be effective by reducing circulating pathogenic IgG and are typically used in generalized, refractory, or high active acetylcholine receptor positive disease, either as a maintenance therapy or to gain rapid, um rapid control.
Muscle-specific kinase-positive disease is fundamentally different. It is largely immunoglobulin G4 or G1 or G3-mediated with minimal complement involvement.
These patients often present with more severe bulbar symptoms and high risk of myasthenia gravis that may present with shortness of breath, difficulty swallowing, or even a crisis.
Cholinesterase inhibitor such as pyridostigmine are frequently ineffective and can paradoxically worsen symptoms with increased fasciculations and clinical deterioration.
Thymectomy has no established role right now, and complement-targeted therapy are not mechanistically appropriate.
FcRn inhibitors and IVIG may still have a role in MuSK-positive patients, particularly for short or intermediate time, but the evidence base is smaller and they are generally adjuncts rather than the primary long term strategy.
What does work for patients with muscle-specific kinase disease is the B-cell depletion, particularly with rituximab, which is many patients produces deep, sustained responses and major steroid-sparing benefit.
For most generalized MuSK-positive patients, rituximab should be considered early in the treatment course rather than reserved as a later stage or sometime reserved as a rescue option when one or other therapy fails.
The take-home message here: Always know your patient’s antibody subtype. It is very important for you to design the appropriate strategy, therapeutic strategy.
It determines which drug helps, which drug harms, and which biologic mechanism, including complement, FcRn FcRn I’m sorry, IVIG, or B-cell depletion you should target.